TriangleNCT03038100 · OUTCOME
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- Not reported
- Time frame
- Baseline to approximately 55 months
Analysis population: PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.
Groups in this outcome
Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
| Group | Source count |
|---|---|
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | 569 |
Reported measurements
Baseline evaluable participants
| Group | Source count |
|---|---|
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | 563 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | 0.7 | Not reported | Not reported | Not reported | Not reported |
Post-baseline evaluable participants
| Group | Source count |
|---|---|
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | 569 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | 22.7 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0.7
- denoms
- counts
- group Id
- OG000
- value
- 563
- units
- Participants
- title
- Baseline evaluable participants
- categories
- measurements
- group Id
- OG000
- value
- 22.7
- denoms
- counts
- group Id
- OG000
- value
- 569
- units
- Participants
- title
- Post-baseline evaluable participants
- denoms
- counts
- group Id
- OG000
- value
- 569
- units
- Participants
- groups
- description
- Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
- id
- OG000
- title
- Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab
- param Type
- NUMBER
- population Description
- PK-evaluable population is defined as patients who received any dose of study medication and who had at least one post-baseline PK sample available.
- reporting Status
- POSTED
- time Frame
- Baseline to approximately 55 months
- title
- Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice